Last reviewed · How we verify

Hu1124 — Competitive Intelligence Brief

Hu1124 (EFALIZUMAB) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD11a-directed Humanized IgG1 Antibody. Area: Immunology.

marketed CD11a-directed Humanized IgG1 Antibody Leukocyte adhesion glycoprotein LFA-1 alpha Immunology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Hu1124 (EFALIZUMAB) — Roche.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Hu1124 TARGET EFALIZUMAB Roche marketed CD11a-directed Humanized IgG1 Antibody Leukocyte adhesion glycoprotein LFA-1 alpha 2003-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD11a-directed Humanized IgG1 Antibody class)

  1. Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hu1124 — Competitive Intelligence Brief. https://druglandscape.com/ci/efalizumab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: